Michael Ball New CEO of GenoLogics, Steven Gullans Leaves US Genomics to Head RxGen, Hans Johansson Joins Sidec Technologies as CEO, Robert Millman Becomes Chief Patent Counsel of Alnylam, and Others

Michael Ball has become the new CEO of GenoLogics, the Victoria, Canada-based company said on Monday. Previously, he held positions as vice president at both Creo and Carmanah Technologies. Company founder James DeGreef will become GenoLogics' president. GenoLogics offers a proteomics laboratory information management system.

Steven Gullans is the new president and CEO of RxGen, the company said on Monday. He will replace Harry Penner, the interim CEO, who will remain chairman of the board. Gullans, a co-founder of RxGen, joins the company from US Genomics, where he was CSO. He holds a PhD in physiology from DukeUniversity and a BS from UnionCollege.

Hans Johansson is the new CEO of Sidec Technologies, the Stockholm-based company said on Monday. He succeeds Gösta Sjöholm, who resigned as CEO but will remain with the company during a transition period. Johansson comes to Sidec from Biotage, where he was president of the BioSystems Division. Prior to that, he was CEO of Personal Chemistry.

Kurt Berens will join CytoGenix as vice president of product development, the Houston-based gene silencing company said yesterday. He used to be a section manager for Wyle Laboratories, Cellular and Biomedical Group, at the NASA-Johnson Space Center in Houston.

Robert Millman has become chief patent counsel of Alnylam Pharmaceuticals, the Cambridge, Mass.-based company said on Monday. He has been a company consultant since 2003. Most recently, Millman was a freelance intellectual property consultant for biotechnology companies and the interim chief patent counsel at Infinity Pharmaceuticals. Prior to that, he was chief IP counsel at Celera Genomics. Millman holds a JD degree from the Washington College of Law at AmericanUniversity. He also holds an MS in genetics from Washington State University and a BS in biochemistry from the Universityof California, Riverside.

Lars Holmkvist has become president of Applied Biosystems Europe, ABI said on Monday. Most recently, he was vice president of vascular and cardiac surgery in Western Europefor Medtronic.

Mehis Pold has become director of research in molecular medicine at CeMines, the Evergreen, Colo.-based company said last week. Since 2000, he has been a researcher in the division of pulmonology at the Universityof California, Los Angeles.

Genospectra has appointed Ron Hahn to its board, the Fremont, Calif.-based company said yesterday. Hahn, a venture capitalist focusing on health care and life sciences, is a partner of Battelle Ventures, which led Genospectra's recent financing round.

Joel Brill has joined the newly created business development advisory board of GenoMed, the St. Louis-based company said today. He is a clinical assistant professor at the Universityof Arizona Schoolof Medicineand the chief medical officer of Predictive Health of Phoenix, Ariz.

Exagen Diagnostics of Albuquerque, NM, has formed an advisory board. Board members are Sanjeev Arora, executive vice chairman of the department of internal medicine at University of New Mexico Health Sciences Center; Michael Fried, a professor of medicine and director of hepatology at the University of North Carolina at Chapel Hill; Robert Gish, director of the divison of hepatology and complex GI at California Pacific Medical Center; and Paul Pockros, division head of gastroenterology/hepatology at Scripps Clinic.

Third Wave Technologies has appointed Lionel Sterling to its board of directors, the Madison, Wis.-based company said last week. He replaces Tom Daniel, who resigned from the board. Most recently, he was a director of I-STAT, a point-of-care diagnostics company.

Promoted? Changing jobs? GenomeWeb News wants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.